No Sale: The Democratic Congress Tries to Roll Back Enrollment in Medicare Advantage
This article was originally published in RPM Report
Executive Summary
Price negotiation has stalled, but the Democratic Congress still wants to put its mark on Medicare Part D. There are plenty of levers to pull that could subtly but profoundly reshape the evolution of this critical new pharma market. One example: cracking down on marketing "abuses" by private Medicare plans.
You may also be interested in...
Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.
Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.
With Enemies Like These: Will the Democrats Make Part D More Pharma Friendly?
The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?